Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Songyi Park, Sang-A Kim, Ji Yun Lee, Ja Min Byun, Jeong-Ok Lee, Youngil Koh, Junshik Hong, Junglim Lee, Soo-Mee Bang, Inho Kim, Sung-Soo Yoon, Dongyeop Shin

Blood (2024) 144 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2024-202293

Published: 2024

Journal Articles

Spectrum of TP53 Mutation in Hematologic Malignancies

Seo Yoon Jang, Joowon Jang, Jee-Soo Lee, Songyi Park, Ja Min Byun, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2024-210051

Published: 2024

Journal Articles

Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses

Ja Min Byun, Sung-Soo Park, Suein Choi, Youngil Koh, Chang-Ki Min, Seunghoon Han

Blood (2024) 144 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2024-198337

Published: 2024

Journal Articles

Rh Antigens Immunogenicity Prediction Using in silico analysis of HLA Binding

Hee-Jeong Youk, Yong-Joon Cho, Ja Min Byun, Yong-Hyun Han, Seong Who Kim, Dae-Hyun Ko

Blood (2024) 144 (Supplement 1): 4028.

https://doi.org/10.1182/blood-2024-202747

Published: 2024

Journal Articles

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Sang Eun Yoon, Sung-Hoon Jung, Gyeong Won Lee, Chang-Ki Min, Ja Min Byun, Jae-Yong Kwak, Myung-Won Lee, Ho Sup Lee, Seok Jin Kim, Kihyun Kim

Blood (2024) 144 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2024-198947

Published: 2024

Journal Articles

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Blood (2024) 144 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2024-205164

Published: 2024

Journal Articles

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Dongchan Kim, Daehyeon Gwak, Ja Min Byun, Youngil Koh, Junshik Hong, Jung Lim Lee, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 1375.

https://doi.org/10.1182/blood-2024-202733

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

T-Cell Depletion with Both Reduced Dose Anti-Thymocyte Globulin and Reduced Dose Post-Transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia and Myelodysplatic Syndrome

Junshik Hong, Dong Hyun Kim, Ja Min Byun, Dongyeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Hyun Jung Lee, Jung Lim Lee

Blood (2023) 142 (Supplement 1): 7000.

https://doi.org/10.1182/blood-2023-185845

Published: 2023

Journal Articles

A Prospective Randomized Study for Optimal Red Blood Cell Use Patients with Acute Myeloid Leukemia Receiving Dose Intensive Chemotherapy

Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Inho Kim, Hyungsuk Kim

Blood (2022) 140 (Supplement 1): 81–82.

https://doi.org/10.1182/blood-2022-157619

Published: 2022

Journal Articles

Serum Erythropoietin As an Early Marker for Hidden Hematologic Malignancy in Anemia of Unknown Etiology

Seong Juyong, Dong-Yeop Shin, Ja Min Byun, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon

Blood (2022) 140 (Supplement 1): 8164–8165.

https://doi.org/10.1182/blood-2022-155698

Published: 2022

Journal Articles

HDAC Inhibition Effectively Induce Apoptosis in Diffuse Large B Cell Lymphoma with High Bfl-1

Eunchae Park, Chansub Lee, Jihyun Park, Jun Liu, Junshik Hong, Dong-Yeop Shin, Ja Min Byun, Youngil Koh, Sung-Soo Yoon

Blood (2021) 138 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2021-148277

Published: 2021

Journal Articles

A Pilot Study of MG4101, Allogeneic Natural Killer Cell, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sang A Kim, Youngil Koh, Miyoung Jung, Yu Kyeong Hwang, Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon

Blood (2021) 138 (Supplement 1): 3835.

https://doi.org/10.1182/blood-2021-152137

Published: 2021

Journal Articles

Prediction of Venetoclax Sensitivity Based on BCL2 Protein-Protein Interaction for Acute Myeloid Leukemia Patients

Ja Min Byun, Changju Chun, Youngil Koh, Tae-Young Yoon

Blood (2021) 138 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2021-150925

Published: 2021

Journal Articles

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ho-Sup Lee, MD PhD, Sung-Soo Yoon, MD PhD, Dong-Yeop Shin, MD PhD, Ja Min Byun, Je-Jung Lee, MD PhD, Sung-Hoon Jung, MD, Chang-Ki Min, MD PhD, Hyo Jung Kim, MD PhD, Byeong Seok Sohn, MD PhD, Sung Hwa Bae, MD, Lee Gyeong-Won, Sungwoo Park, MD, Young Rok Do, PhDMD, Hyun Jung Lee, MD, Min Kyoung Kim, Yoo Jin Lee, MD PhD

Blood (2019) 134 (Supplement_1): 4372.

https://doi.org/10.1182/blood-2019-127707

Published: 2019

Journal Articles

Leukemic Stem Cell Phenotype Is Associated with Mutational Profile in Acute Myeloid Leukemia

Ja Min Byun, MD, Dong-Yeop Shin, MD PhD, Youngil Koh, Sung-Soo Yoon, MD PhD, Junshik Hong, MD, Inho Kim, MD PhD

Blood (2019) 134 (Supplement_1): 3852.

https://doi.org/10.1182/blood-2019-126373

Published: 2019

Journal Articles

A Nationwide Epidemiologic Study for Disease Transformation and Secondary Cancers in Korean Patients with Myeloproliferative Neoplasms

Junshik Hong, MD, Ju Hyun Lee, Ja Min Byun, MD, Ji Yun Lee, MD, Hyun Jung Lee, MD, Sang Mee Hwang, MD PhD, Byung-Su Kim, MD PhD, Hyo Jung Kim, MD PhD, Jung Lim Lee, MD, Dong-Yeop Shin, MD PhD, Youngil Koh, MD PhD, Sung-Soo Yoon, MD PhD, Soo-Mee Bang, MD PhD

Blood (2018) 132 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2018-99-116298

Published: 2018

NARROW

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Spectrum of TP53 Mutation in Hematologic Malignancies

Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses

Rh Antigens Immunogenicity Prediction Using in silico analysis of HLA Binding

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

T-Cell Depletion with Both Reduced Dose Anti-Thymocyte Globulin and Reduced Dose Post-Transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia and Myelodysplatic Syndrome

A Prospective Randomized Study for Optimal Red Blood Cell Use Patients with Acute Myeloid Leukemia Receiving Dose Intensive Chemotherapy

Serum Erythropoietin As an Early Marker for Hidden Hematologic Malignancy in Anemia of Unknown Etiology

HDAC Inhibition Effectively Induce Apoptosis in Diffuse Large B Cell Lymphoma with High Bfl-1

A Pilot Study of MG4101, Allogeneic Natural Killer Cell, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prediction of Venetoclax Sensitivity Based on BCL2 Protein-Protein Interaction for Acute Myeloid Leukemia Patients

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Leukemic Stem Cell Phenotype Is Associated with Mutational Profile in Acute Myeloid Leukemia

A Nationwide Epidemiologic Study for Disease Transformation and Secondary Cancers in Korean Patients with Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only